The US on Friday approved the first blood test for Alzheimer's, a move that can help patients begin treatment earlier with ...

The father of the dominant theory of Alzheimer’s disease told another eminent researcher he is “causing harm” by criticizing his theory ...

The United States on Friday approved the first blood test for Alzheimer's, a move that could help patients begin treatment ...

The FDA-approved monoclonal antibody infusion known as donanemab, is showing promise to reduce cognitive decline among ...

The United States yesterday approved the first blood test for Alzheimer’s, a move that could help patients begin treatment ...

Significant adverse events — such as ARIA — with lecanemab, the drug that slows Alzheimer's, is rare and manageable, ...

Explore why INmune Bio, Inc. is a speculative Strong Buy for high-risk investors. Click for the upcoming catalysts that make ...

While many pharma and biotech companies developing drugs to treat Alzheimer's disease are targeting amyloid beta plaque, Eli ...

LEXINGTON For the past four decades, the University of Kentucky's Sanders-Brown Center on Aging (SBCoA) has been at the ...

For the past four decades, the University of Kentucky’s Sanders-Brown Center on Aging has been at the forefront of Alzheimer’s disease research, making groundbreaking discoveries that have shaped expe ...

Lecanemab and donanemab (Kisunla), another anti-amyloid treatment, won approval based on evidence that they slowed cognitive ...

A world-leading experimental dementia drug designed to prevent the disease before it begins will be trialled in Australia for ...